Bringing effective new treatment options to patients who need them
Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers.
Our lead asset is an off-the-shelf (allogeneic) cell therapy, azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers.
We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.
We believe Imugene’s cellular therapy may become foundation treatments for cancer and our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.
